NAT-SUNITINIB CAPSULE

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

SUNITINIB (SUNITINIB MALATE)

Доступна з:

NATCO PHARMA (CANADA) INC

Код атс:

L01EX01

ІПН (Міжнародна Ім'я):

SUNITINIB

Дозування:

50MG

Фармацевтична форма:

CAPSULE

Склад:

SUNITINIB (SUNITINIB MALATE) 50MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Огляд продуктів:

Active ingredient group (AIG) number: 0151642003; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2023-06-30

Характеристики продукта

PRODUCT MONOGRAPH
PR
NAT-SUNITINIB
Sunitinib capsules
Capsules, 50 mg sunitinib (as sunitinib malate), Oral
Tyrosine Kinase Inhibitor, Anti-Tumour Agent
Natco Pharma (Canada) Inc.
2000 Argentia Road, Plaza 1, Suite 200
Mississauga, Ontario
L5N 1P7
Date of Initial Authorization:
June 29, 2023
Submission Control No.: 254828
_NAT-SUNITINIB Product Monograph _
_Page 2 of 69 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
17
DRUG INTERACTIONS
.................................................................................................
32
DOSAGE AND ADMINISTRATION
.............................................................................
33
OVERDOSAGE
................................................................................................................
34
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 34
STORAGE AND STABILITY
.........................................................................................
38
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 39
PART II: SCIENTIFIC
INFORMATION...............................................................................
40
PHARMACEUTICAL INFORMATION
.........................................................................
40
CLINICAL TRIALS
...